Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer

The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n=534) or malignant (n=831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.

[1]  A. Dnistrian,et al.  Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. , 1991, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[2]  A. van Dalen,et al.  Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[3]  R. Nagler,et al.  Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21‐1 and TPS in oral squamous cell carcinoma , 1999, Cancer.

[4]  W. Putten,et al.  The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer , 1997, Journal of Cancer Research and Clinical Oncology.

[5]  A. Dnistrian,et al.  CA 549 as a Marker in Breast Cancer , 1991, The International journal of biological markers.

[6]  A. Zetterberg,et al.  Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. , 1996, European journal of biochemistry.

[7]  M. Ali,et al.  Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  A. Nicolini,et al.  Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. , 1991, British Journal of Cancer.

[9]  M. Kerin,et al.  Tissue polypeptide specific antigen (TPS) in breast cancer--an initial evaluation. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  R. Gelman,et al.  Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. , 1988, Cancer research.

[11]  P. Sismondi,et al.  TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. , 1996, Anticancer research.

[12]  Á. Ruibal,et al.  Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease , 1989, Cancer.

[13]  L. Hefler,et al.  Tissue polypeptide specific antigen in the follow‐up of ovarian and cervical cancer patients , 1998, International journal of cancer.

[14]  A. V. Dalen.  TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3. , 1992 .

[15]  D. Hayes,et al.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. , 1985, The Journal of clinical investigation.

[16]  C. Loprinzi,et al.  Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Martín Velasco,et al.  Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[18]  V. Björklund,et al.  Antigenicity of Pooled Human Malignant and Normal Tissues by Cyto-Immunological Technique: Presence of an Insoluble, Heat-Labile Tumor Antigen , 1957 .

[19]  M. McGuckin,et al.  CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer , 1995, Breast Cancer Research and Treatment.

[20]  E. Röttinger,et al.  Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer , 1989, The International journal of biological markers.

[21]  V. Kosma,et al.  Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. , 1997, Anticancer research.

[22]  C. Sturgeon,et al.  Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes , 1996 .

[23]  F. Guadagni,et al.  A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  CA549 and TPS Patterns in the Diagnosis and Staging of Patients with Breast Carcinoma , 1996, The International journal of biological markers.

[25]  M. Kallioinen,et al.  Expression of cytokeratins in regenerating human epidermis , 1995, The British journal of dermatology.

[26]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[27]  A. Semjonow,et al.  Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen , 2004, World Journal of Urology.

[28]  A. Recchioni,et al.  Serum markers for monitoring of prostatic carcinoma , 1997, The Prostate.

[29]  D. Hayes,et al.  Circulating tumor markers in breast cancer. , 1989, Hematology/oncology clinics of North America.

[30]  A. van Dalen,et al.  The Prognostic Significance of Increasing Marker Levels in Metastatic Breast Cancer Patients with Clinically Complete Remission, Partial Remission or Stable Disease , 1998, The International journal of biological markers.

[31]  R. Molina,et al.  c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value , 1998, Breast Cancer Research and Treatment.

[32]  S. Krämer,et al.  Breast cancer and clinical utility of CA 15-3 and CEA. , 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[33]  E. Röttinger,et al.  The value of the tumor marker CA 15‐3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen , 1991, Cancer.

[34]  A. Dnistrian,et al.  CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[35]  V. Zurawski,et al.  Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Novaković,et al.  Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients. , 1996, Cancer letters.

[37]  V. Barak,et al.  Cytokeratin markers in malignant pleural mesothelioma. , 1998, Cancer detection and prevention.

[38]  A. Zygmunt,et al.  Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. , 1999, European journal of gynaecological oncology.

[39]  A. van Dalen.  TPS monitoring in metastatic breast cancer. , 1999, The International journal of biological markers.

[40]  M. Brizzi,et al.  Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[41]  J. Pujol,et al.  Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer. , 1994, European journal of cancer.

[42]  R. Molina,et al.  Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. , 1995, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[43]  D. Pons-Anicet,et al.  Value of CA 15:3 in the follow-up of breast cancer patients. , 1987, British Journal of Cancer.